GAS5 and neoplasm: In our current study, we found that GAS5 expression was significantly lower in tumors from patients with advanced disease (76.6%, P < 0.001), relative to that in adjacent noncancerous tissues, as evidenced by larger tumor size, higher TNM stage, and higher incidences of ulceration and metastasis, compared to those of patients whose tumors expressed levels of GAS5 that were higher than those in their control tissues (Table 1).